To see the effect of Unani formulation as an add-on therapy along with Allopathic treatment in the Covid-19 patients

Clinical Evaluation of a Unani formulation as adjunct therapy/add-on therapy simultaneously with the Allopathic treatment (regimen specific) in the Covid-19 patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032647

Enrollment

Registered

2021-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: 1. Habbe Zehrmohra 2. Habbe Tabasheer: 1. Habbe Zehrmohra one tablet of 250 mg twice daily orally for 14 days 2. Habbe Tabasheer two tablet of 250 mg each twice daily orally for14 days

Eligibility

Inclusion criteria

Inclusion criteria: RT-PCR confirmed diagnosis of COVID-19 Provides written informed consent Male or non-pregnant, non-lactating female aged more than 18 years upto 60 years Participants with clinical syndrome associated with COVID -19 infection, presenting with either: Uncomplicated upper respiratory tract viral infection, with non-specific symptoms such as fever, cough, sore throat, nasal congestion, sneezing/running nose, loss of taste and smell, shortness of breath OR Mild pneumonia with no signs of severe pneumonia or need of supplemental oxygen therapy Able to take the drug orally and comply with study procedures

Exclusion criteria

Exclusion criteria: Participants with severe COVID-19 symptoms with respiratory rate > 30 breaths / min and severe respiratory distress or SpO2 Participants with altered mental state Laboratory abnormalities at Screening, including any of the following: (a)AST or ALT > 2.5 times ULN (upper limit of normal) (b) Absolute neutrophil count (c) Serum Creatinine > ULN (d) Total bilirubin > ULN Participants with active hepatitis, tuberculosis and definite bacterial or fungal infections Participants with multiple organ failure requiring ICU monitoring and treatment Participants of respiratory failure and requiring mechanical ventilation Participants with persistent vomiting Participants with shock Patient who have participated in another investigational study within 3 months prior to enrolment in this study

Design outcomes

Primary

Measure	Time frame
1.RT-PCR for Covid-19 2. IL-6 and TNF-alfa 3. IGg and IGm 4. CRPTimepoint: Day Zero, 7th day and day15	—

Secondary

Measure	Time frame
Clinical parametersTimepoint: Day Zero, 7th day and day15	—

Countries

India

Contacts

Public ContactProf Dr Suhail Fatima

Jamia Hmadard

sfatima@jamiahamdard.ac.in9891306067

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026